{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 49,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/43",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.12,
        "x": 0.83,
        "y": 0.18
      },
      "kind": "image",
      "text": "Syringe graphic",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77a08460-6e03-4bea-9c3e-e539aa16f555",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Precision medicine approach to radiation therapy, a validated tumor-killing technology. Lead clinical program currently in Phase 1 development targeting IGF-1R, showing uptake in multiple tumor types. Proprietary Fast-Clear linker technology facilitates faster clearance of non-tumor localized drug, improving the therapeutic window. Platform technology can be used with multiple antibodies to enable pipeline expansion. Strong internal R&D and manufacturing capabilities and expertise, a barrier to entry into the radiopharmaceutical space that has recently experienced significant M&A and partnering activity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a4353b9-5f50-4135-bebb-23b0af2950c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "title",
      "text": "Opportunity to develop potent, targeted therapies based upon Fusion's platform technology treating a broad range of cancer types",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0377191-e369-4b2e-9381-b8b460b44617",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Creating Next Generation Radiopharmaceuticals for Precision Oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3763044-f96a-4d24-92e2-7525c072e2e6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "e31c7d53-25e1-4bea-b167-40c12bfee097",
      "evidence": "Opportunity to develop potent, targeted therapies based upon Fusion's platform technology treating a broad range of cancer types",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}